Want to join the conversation?
Drug maker $AGN reported a narrower 3Q15 loss from continuing operations on higher benefit for income taxes. Loss from continuing operations narrowed to $854.8MM or $2.35 per share from $1.16Bil or $4.40 per share last year. Revenue grew to $4.09Bil from $2.15Bil. Non-GAAP EPS from continuing operations rose to $3.48 from $2.11.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)